Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065011 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B
A Phase 2 study of Usher's Syndrome, sponsored by Sanofi.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT02065011: Active Phase 2 study of Usher's Syndrome, sponsored by Sanofi.
NCT02065011 is a Phase 2 study of Usher's Syndrome that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02065011, a Phase 2 study of Usher's Syndrome, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
Primary Outcome
The number and percentage of patients with treatment emergent adverse events
Conditions Studied
Interventions
- DRUG Blood draw for the laboratory assessment
Study Locations (2)
Oregon
- Oregon Health and Science University Site Number : 840001 - Portland
Other
- Investigational Site Number : 250001 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-09-12 |
| Est. Completion | 2031-06-13 |
| Phase | Phase 2 |
What the registry record for NCT02065011 still lists
NCT02065011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Usher's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for the laboratory assessment is the first listed.
NCT02065011 reports a single indexed study location in Oregon, Other.
Frequently Asked Questions
What is clinical trial NCT02065011 about?
NCT02065011 is a clinical study titled "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B". Primary Objective: To evaluate the long-term safety and tolerability of SAR421869 in patients with Usher syndrome Type 1B Secondary Objective: To assess long-term safety and biological activity of SAR421869
What is the current status of trial NCT02065011?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-09-12. Estimated completion is 2031-06-13.
What conditions does trial NCT02065011 study?
This clinical trial studies the following conditions: Usher's Syndrome.
What interventions are being tested in trial NCT02065011?
The interventions under investigation include: Blood draw for the laboratory assessment (DRUG).
Who is sponsoring clinical trial NCT02065011?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065011 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02065011's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI